

News Release

Heather Connor
781-681-2124

April 17, 2012

EMD Serono, Inc. Founding Donor of Newly Launched MGH Multiple Sclerosis Discovery Forum

- **\$1.5M grant given to Massachusetts General Hospital (MGH) went toward funding the development of the Multiple Sclerosis Discovery Forum website**
- **EMD Serono is committed to investing in the understanding of neurological disorders**

Rockland, Massachusetts, April 17, 2012 – EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is the founding donor of the newly launched Multiple Sclerosis (MS) Discovery Forum website (<http://www.msdiscovery.org>), a joint project of MassGeneral Institute for Neurodegenerative Disease (MIND), nonprofit organization Accelerated Cure Project for MS and the Max Planck Institute for Molecular Genetics. EMD Serono provided a grant of \$1.5M to MGH to develop and launch the site, which provides an interactive virtual environment for members of the MS research community to engage in on-line discussions and collaborations to speed the development of treatments. This grant reflects EMD Serono's ongoing commitment to investing in the understanding of neurological diseases.

"EMD Serono is proud to have provided the necessary foundation for MGH to develop this website that allows experts in the MS community to interact in a unique space designed to spark innovation based on collaboration," said Steve Arkinstall, PhD, Senior Vice President and Head of Global External Innovation and US Research for EMD Serono, Inc. "It is critical to leverage the connectivity that social media provides, to expand the knowledge base of MS and advance our understanding of the disease as we work toward discovering new treatment options in MS."

The MS Discovery Forum is an impartial space that will afford the MS research community numerous benefits, including access to a custom drug-pipeline database and the MSGene database of MS genetic association studies, the ability to participate in peer-hosted discussion forums and webinars, the ability to share and receive feedback from other researchers on study findings and key learnings and the opportunity to learn about breakthrough findings through original articles by highly regarded science writers.

The Accelerated Cure Project for MS (ACP) creates the site's content, the MassGeneral Institute for Neurodegenerative Disease (MIND) has developed and supports the site's platform; and the Max

News Release

Planck Institute for Molecular Genetics curates MSGene. The site is a free resource and is guided by a distinguished scientific advisory board representing various MS research institutions.

EMD Serono has a decade long commitment to serving the needs of those living with Multiple Sclerosis, providing an important treatment option for relapsing MS as well as devices and patient support services.

For more information about the site and to register as a member of the MSDF, please visit www.msdiscovery.org.

About multiple sclerosis

Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About Rebif® (interferon beta-1a)

Rebif is used to treat relapsing forms of MS to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS. Rebif is not approved for treatment of chronic progressive MS. Rebif is available in 22 mcg and 44 mcg prefilled, preassembled syringes and a titration pack by prescription only. Before beginning treatment, patients should discuss with their doctor the potential benefits and risks associated with Rebif. Let your doctor know if you have a history of depression, seizures, liver disease, thyroid problems, or blood cell count or bleeding problems, or if you have had previous allergic reactions to medications. Tell your doctor about all medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Rebif and other medicines may affect each other causing serious side effects. Talk to your doctor before you take any new medicines. Rebif is not recommended for women who are or plan to become pregnant.

Potential serious side effects of Rebif include depression and risk of suicide, liver problems, risk to pregnancy, injection-site problems, and severe allergic reactions. Allergic reactions are rare and may be associated with difficulty in breathing and loss of consciousness, which require immediate medical attention.

The most common side effects with Rebif are injection-site reactions, flu-like symptoms (fever, chills, muscle aches, tiredness), depression, abdominal pain, increased liver enzymes, and blood cell count decreases. Let your doctor know if you have any of these symptoms or feel sad, tired, hot or cold, or experience hives, rashes, bruising, yellowing of the skin, or a change in body weight (gain or loss).

This information is not intended to replace discussions with your doctor. For additional information about Rebif, please consult the Prescribing Information and Medication Guide at www.emdserono.com and talk to your doctor. You can also visit www.ms lifelines.com or call toll-free 1-877-44-REBIF (1-877-447-3243). Rebif is available by prescription only.

About EMD Serono, Inc.

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif® (interferon beta-1a), as well as in endocrinology, with Saizen® (somatropin (rDNA origin) for injection), Serostim® (somatropin (rDNA origin) for injection) and EGRIFTA® (tesamorelin for injection). EMD Serono is a leader in reproductive health, with Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa for injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection). In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more

News Release

than 10 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 1,100 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.

For more information, please visit www.emdserono.com

About Merck KGaA

Merck is a global pharmaceutical and chemical company with total revenues of € 10.3 billion in 2011, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit www.merckserono.com or www.merckgroup.com